Lv3
290 积分 2024-03-04 加入
Zhou Q, Yu Y, Xing L, et al. First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial. Med. 2025;6(1):100513. doi:10.1016/j.medj.2024.09.002
2小时前
待确认
Adjuvant Chemotherapy for High-risk Pathologic Stage I Non-Small Cell Lung Cancer
1个月前
已关闭
Clinical characteristics and medical service utilization of lung cancer in China, 2005-2014: Overall design and results from a multicenter retrospective epidemiologic survey
1个月前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
1个月前
已关闭
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC
1个月前
已完结
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
2个月前
已完结
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
2个月前
已完结
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
2个月前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC
3个月前
已完结
P3.12.17 A Phase II Study of Firmonertinib Combined With Apatinib as First-Line Therapy in NSCLC Patients With EGFR Uncommon Mutations
4个月前
已关闭
皖公网安备34019202002308
